FEMASYS INC. DL -,001

Femasys entered into an omnibus amendment agreement that removes the adjustment clause for a stock split from the terms of its secured, convertible senior notes and warrants, effective December 31, 2025. In return, the company is issuing 16,378,563 Series D-1 warrants with an exercise price of 0.58 USD; the securities are being issued to accredited investors without registration. Board member Joshua Silverman resigned, and Dr. Kenneth D. Eichenbaum was appointed as an independent director until the 2026 annual meeting. In parallel, Femasys has started patient enrollment for the pivotal FINALE study, received a CPT category III code for FemaSeed, and reports, according to data, negative third-party financed free cash flow of about 20 million USD; analyst Lake Street recommends buy with a 1.50 USD price target. » More on de.investing.com

Femasys has begun recruitment for the FINALE study, a prospective, multicenter, single-arm trial to assess the safety and effectiveness of the non-surgical contraceptive FemBloc under an FDA-IDE. The primary endpoint is the pregnancy rate after one year in 401 women, with an interim analysis after 300 completed one-year observations; participants will be followed for five years. FemBloc is already approved in Europe, the United Kingdom and New Zealand, but the study is rapidly consuming cash while analysts see price targets between $1.50 and $6.50. » More on de.investing.com

The CPT Editorial Panel of the American Medical Association approved a Category III CPT code for intratubal insemination with FemaSeed, effective January 1, 2027. The code covers the use of FemaSeed, which in a regulatory pivotal study produced more than double the pregnancy rates versus IUI in cases of low sperm count and is approved in the US, Europe, the UK, Canada and Israel. Femasys recently reported 64% revenue growth while remaining unprofitable and is currently recruiting participants for the US FDA pivotal trial for approval of FemBloc. » More on de.investing.com